Loading company…
VISEN Pharmaceuticals develops medicines for endocrine-related conditions in children and adults.
VISEN Pharmaceuticals develops endocrine therapies, including lonapegsomatropin and navepegritide for pediatric conditions and palopegteriparatide for chronic hypoparathyroidism. Founded in 2018, it is based in Suzhou, China, with offices in Shanghai, Beijing, Hong Kong, and Taipei. In March 2025, it raised USD 72 million in Pre-IPO funding and was listed on the Hong Kong Stock Exchange and Clearing Limited.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in